Advanced Search

 

Study ID Status Title Patient Level Data
MAB108115 Completed A randomised, double-blind, dose escalating study in healthy volunteers to assess the safety, tolerability, extra pulmonary pharmacodynamics and pharmacokinetics of single doses of GSK961081 (succinate salt) Study Listed on ClinicalStudyDataRequest.com
MAB110123 Completed A randomized, double-blind, crossover study to investigate the bronchodilatation post-inhalation of GSK961081 alone and with the addition of cumulative doses of short acting bronchodilators (salbutamol and ipratropium bromide) in patients with COPD Study Listed on ClinicalStudyDataRequest.com
MAB110553 Completed A study to investigate the relative pharmacological activity of aninhaled B2-agonist/anticholinergic dual pharmacophore inhealthy volunteers Study Listed on ClinicalStudyDataRequest.com
MAD103894 Completed A 28 day, Polysomnographic and Subjective Assessment of GW679769 for the Treatment of Primary Insomnia: A Randomized, Double-blind, Parallel-Group, Placebo-Controlled Trial.
MAD105514 Completed A randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of GW679769 on polysomnographic sleep recordings, subjective sleep assessment, and daytime cognitive function in elderly and non-elderly subjects with primary insomnia
MAD105516 Completed A randomized, double-blind, placebo-controlled, crossover study to evaluate the effects of morning administration of GW679769 (10mg and 30 mg) on polysomnograph sleep recordings, subjective sleep assessment, daytime cognition and psychomotor function in subjects with primary insomnia
MAG103114 Completed A single-blind, single dose, placebo controlled, parallel group, first time in human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of ascending IV doses of GSK249320 in healthy volunteers Study Listed on ClinicalStudyDataRequest.com
MD7108238 Completed A placebo-controlled, randomized, dose rising study to evaluate the safety, tolerability and pharmacokinetics of single and repeat ocular doses of pazopanib in healthy adult and elderly subjects.
MD7108240 Completed A double-masked, randomized, parallel-group study to investigate the pharmacodynamics, safety, and systemic pharmacokinetics of pazopanib drops, administered for 28 days to adult subjects with neovascular age-related macular degeneration.
MD7110861 Completed An open-label, two-period, fixed-sequence study in Healthy volunteers to evaluate the effects of repeat oral dosing of ketoconazole on the pharmacokinetics of a single dose of pazopanib (GW786034) administered as eye drops
MD7111396 Completed An extension study to protocol MD7108240: pazopanib eye drops in subjects with neovascular age-related macular degeneration
MEE103219 Completed A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years (Study MEE103219) Study Listed on ClinicalStudyDataRequest.com
MEE103226 Completed A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Provide a Preliminary evaluation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Intravenous anti-human interleukin-5 (mepolizumab, 750mg and 1500mg) in the treatment of Eosinophilic Oesophagitis in Adults Study Listed on ClinicalStudyDataRequest.com
MEK111054 Completed An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor GSK1120212 in Subjects with Solid Tumors or Lymphoma
MET111516 Completed An Open-label, Randomized, Two-way Balanced Crossover Study to Investigate the Bioavailability of two forms ofGSK1363089 in Subjects with Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MET111643 Completed A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects with Metastatic Gastric Cancer Study Listed on ClinicalStudyDataRequest.com
MET111644 Completed A Phase 2 Study of the c-Met RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects with Papillary Renal-Cell Carcinoma Study Listed on ClinicalStudyDataRequest.com
MET111646 Completed A Phase 2 Study of the MET RTK Inhibitor GSK1363089 (formerly XL880) in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Study Listed on ClinicalStudyDataRequest.com
MET111647 Completed A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MET111648 Completed A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects with Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MHE104317 Recruiting An Open-Label Compassionate Use access and Long-Term Access Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome
MKC101614 Completed A 28-day, randomised, double-blind, placebo-controlled study to assess the safety, tolerability, anti-inflammatory effect and steady-state pharmacokinetics of SB-681323 7.5 mg per day in patients with chronic obstructive pulmonary disease.
MKI102428 Completed A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD) Study Listed on ClinicalStudyDataRequest.com
MKI106209 Completed A randomised, double-blind, placebo-controlled parallel study to assess the safety, tolerability,pharmacodynamics and steady state pharmacokinetics of repeated doses of GW856553 in patients with COPD
MKN106762 Completed A double-blind placebo-controlled study of the efficacy and safety of the P38 Map Kinase inhibitor SB681323 in patients with neuropathic pain following nerve trauma

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.